Patents Issued in October 24, 2024
-
Publication number: 20240352435Abstract: An object is to provide a plant genome editing technique with higher genome editing efficiency. This object is achieved by a polynucleotide comprising a site-specific nuclease expression cassette and a sequence that binds to a nuclear translocation factor and/or an intranuclear structure, the site-specific nuclease expression cassette comprising (b) a site-specific nuclease coding sequence and (c) a 3?UTR comprising a terminator.Type: ApplicationFiled: August 19, 2022Publication date: October 24, 2024Applicant: GRA&GREEN INC.Inventors: Masaki NIWA, Takehito KOBAYASHI, Yu SAWAI, Atsushi OKUDA
-
Publication number: 20240352436Abstract: Provided is a genome editing technique that achieves higher genome editing efficiency. Any of Proteins 1 to 3 of the present invention.Type: ApplicationFiled: August 22, 2022Publication date: October 24, 2024Applicant: GRA&GREEN INC.Inventor: Takehito KOBAYASHI
-
Publication number: 20240352437Abstract: Methods and compositions are provided for engineering mutant enzymes with reduced star activity where the mutant enzymes have a fidelity index (FI) in a specified buffer that is greater than the FI of the non-mutated enzyme in the same buffer.Type: ApplicationFiled: July 2, 2024Publication date: October 24, 2024Applicant: New England Biolabs, Inc.Inventors: Zhenyu Zhu, Aine Quimby, Shengxi Guan, Dapeng Sun, Yishu Huang, Xuhui Lai, Siu-hong Chan, Xianghui Li, Shuang-Yong Xu, Chunhua Zhang
-
Publication number: 20240352438Abstract: The present invention relates to novel uses of the polypeptides and novel variants of said polypeptides capable of detoxifying Ochratoxin A (OTA) and methods (e.g., for detoxifying mycotoxins) based thereon. The present invention further relates to compositions, kits, transgenic plants, transgenic seeds, transgenic pollen grains, foodstuff, intermediate foodstuff; fodder, intermediate fodder; feed, intermediate feed; additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive); detoxifying agent, intermediate detoxifying agent; nutritional supplement, intermediate nutritional supplement, prebiotic, intermediate prebiotic and/or mixture/s thereof comprising one or more of the polypeptides and/or variants capable of detoxifying Ochratoxin A (OTA).Type: ApplicationFiled: August 26, 2022Publication date: October 24, 2024Inventors: Shreenath PRASAD, Christoph GONAUS, Wulf-Dieter MOLL, Gerd SCHATZMAYR, Sven BENSON, Philipp SCHELLENBERGER, Lenz LORENZ
-
Publication number: 20240352439Abstract: The inventors have made TadA variants with improved activities, such as improved based editing in certain genomic contexts and altered editing window. Aspects of the disclosure relate to a polypeptide comprising SEQ ID NO: 1, wherein the polypeptide comprises one or more amino acid substitutions relative to SEQ ID NO: 1, wherein the one or more amino acid substitutions comprise a substitution at amino acid (23, 27, 36, 47, 48, 51, 76, 82, 106, 108, 109,110, 111, 114, 119, 122, 123, 126, 127, 146, 147, 152, 154, 155, 156, 157, 161, 166, 167), and combinations thereof.Type: ApplicationFiled: September 2, 2022Publication date: October 24, 2024Applicant: THE UNIVERSITY OF CHICAGOInventors: Weixin TANG, Yulan XIAO
-
Publication number: 20240352440Abstract: Disclosed herein are methods of producing hexoses from saccharides by enzymatic processes. The methods utilize fructose 6-phosphate and at least one enzymatic step to convert it to a hexose.Type: ApplicationFiled: April 22, 2024Publication date: October 24, 2024Applicant: BONUMOSE, INC.Inventors: Daniel Joseph WICHELECKI, Edwin O. ROGERS
-
Publication number: 20240352441Abstract: The present invention relates to a method for reducing endotoxin levels or removing endotoxins from nucleic acids. For this a non-ionic detergent selected from the group of alkylglycosides and secondary alcohol alkoxylates or mixtures thereof is added prior or during anion exchange chromatographic purification of the nucleic acids using a membrane or monolith-based sorbent.Type: ApplicationFiled: August 3, 2022Publication date: October 24, 2024Applicant: MERCK PATENT GMBHInventors: Anja HEINEN-KREUZIG, Andre KIESEWETTER, Andreas STEIN, Akshat GUPTA
-
Publication number: 20240352442Abstract: The present disclosure relates to a method for attenuating an influenza virus, an attenuated influenza virus strain and use thereof, and belongs to the technical field of attenuated vaccines. In the present disclosure, the method includes the following steps: conducting synonymous mutation on an overlap of an M2 gene and an M1 gene in an M gene of an influenza A virus, while ensuring integrity and invariance of an amino acid sequence encoded by the M1 gene; conducting mutation into termination codon and deletion of partial nucleotide sequence in a transmembrane domain of the M2 gene, and rescuing an attenuated influenza virus strain using a reverse genetic system.Type: ApplicationFiled: April 21, 2023Publication date: October 24, 2024Inventors: Shuihua MAO, Mengyun ZHOU, Ruiting CHEN, Xiaofei LIU, Jiasheng SONG
-
Publication number: 20240352443Abstract: The present invention relates to a method for generating a double-stranded nucleic acid having a predetermined sequence and a method for producing a double-stranded polynucleotide of interest. The invention further relates to a kit for the implementation of said methods.Type: ApplicationFiled: July 22, 2022Publication date: October 24, 2024Inventors: Sandrine CRETON, Florence MAHE
-
Publication number: 20240352444Abstract: High-throughput methods for screening large populations of variant proteins are provided. The methods utilize large-scale arrays of microcapillaries, where each microcapillary comprises a solution containing a variant protein, an immobilized target molecule, and a reporter element. Immobilized target molecules may include any molecule of interest, including proteins, nucleic acids, carbohydrates, and other biomolecules. The association of a variant protein with a molecular target is assessed by measuring a signal from the reporter element. The contents of microcapillaries identified in the assays as containing variant proteins of interest can be isolated, and cells expressing the variant proteins of interest can be characterized. Also provided are systems for performing the disclosed screening methods.Type: ApplicationFiled: April 19, 2024Publication date: October 24, 2024Inventors: Jennifer R. Cochran, Bob Chen, Spencer Caleb Alford
-
Publication number: 20240352445Abstract: The present disclosure discloses a method for identifying an optimized protein. The method involves constructing and targeting targeted libraries against a target antigen using a first set of selection conditions to select a pool of binders in each library, combining the selected libraries into one or more libraries; and selecting the combined library against the target antigen using a second set of selection conditions to identify at least one protein having an optimized functional profile. An exemplar protein that can be identified with this method is an antibody or a fragment thereof.Type: ApplicationFiled: August 15, 2022Publication date: October 24, 2024Inventors: Toshiaki MARUYAMA, Shigeru CJ Okumura, Kevin ENTZMINGER
-
Publication number: 20240352446Abstract: The invention relates, in part, to methods and systems with which to combine methods of determining an activity of a gene of interest and the gene's sequence, thereby allowing the genotype and associated phenotype to be determined in a single sequencing step.Type: ApplicationFiled: August 23, 2022Publication date: October 24, 2024Applicant: Massachusetts Institute of TechnologyInventors: Kevin Michael Esvelt, Boqiang Tu
-
Publication number: 20240352447Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.Type: ApplicationFiled: June 21, 2024Publication date: October 24, 2024Applicant: New England Biolabs, Inc.Inventors: Zhenyu Zhu, Aine Quimby, Shuang-Yong Xu, Shengxi Guan, Hua Wei, Penghua Zhang, Dapeng Sun, Siu-hong Chan
-
Publication number: 20240352448Abstract: Provided are methods of preparing source identifiable collections of nucleic acids from a plurality of sources, such as cells or cell nuclei, using a combinatorial indexing methodology. Generally, the methods include providing a first set of cellular source sub-portions, each sub-portion comprising multiple cellular sources of the initial plurality of cellular sources. First identifier tagged nucleic acids are then generated in the multiple cellular sources of each sub-portion of the first set using a template switching mediated reaction employing a template switch oligonucleotide comprising a first identifier, wherein the first identifier of the template switch oligonucleotides employed in the different sub-portions of the first set is the same within a given sub-portion but differs between the different sub-portions.Type: ApplicationFiled: December 22, 2022Publication date: October 24, 2024Inventors: Kazuo Tori, Magnolia Bostick, Peng Xu, Sally X. Zhang, Szuyuan Eric Pu, Yue Yun, Andrew A. Farmer
-
Publication number: 20240352449Abstract: Disclosed herein are methods for isolating DNA, such as cell-free DNA (cfDNA) or DNA from a tissue sample, e.g., in which the DNA is partitioned into hypermethylated and hypomethylated partitions. After differential tagging of the partitions, portions of the hypomethylated partition are pooled with the hypermethylated partition or pooled separately. Epigenetic and sequence-variable target regions are captured from the pool comprising DNA from the hypermethylated and hypomethylated partitions, and sequence-variable target regions are captured from the pool comprising DNA from the hypomethylated partition. This approach can reduce costs and/or bandwidth by limiting sequencing of epigenetic target regions from the hypomethylated partition, which may be less informative than other DNA.Type: ApplicationFiled: February 27, 2024Publication date: October 24, 2024Applicant: GUARDANT HEALTH INC.Inventors: Ariel JAIMOVICH, Sven Jeffrey DUENWALD, Peter Vilem GRAUMAN, Yupeng HE, Charbel Said EID, Haley Dara AXELROD
-
Publication number: 20240352450Abstract: Embodiments herein describe systems and methods to determine nucleic acid thermodynamics and uses thereof. Many embodiments utilize a sequencing chip, such as an Illumina flow cell as a high-throughput platform for performing massively parallel melt curve determination. In many embodiments, nucleic acid molecules possessing a region that forms a secondary structure are affixed to a sequencing chip and hybridized with one or more labeled oligonucleotides. As the secondary structure denatures, changes in fluorescence can be measured to determine a melt curve of specific sequences.Type: ApplicationFiled: August 29, 2022Publication date: October 24, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Hannah K. Wayment-Steele, Eesha Sharma, Rhiju Das, William J. Greenleaf, Anthony Ho, Winston Becker, Yuxi Ke
-
Publication number: 20240352451Abstract: The invention relates to improved methods of loading aqueous reagents into electrowetting devices which are often hydrophobic and therefore problematic to load. Disclosed is a method for moving an aqueous droplet from an inlet port onto an EWoD device by actuating a temporary inlet path.Type: ApplicationFiled: July 21, 2022Publication date: October 24, 2024Inventors: Michael Jan Horka, Sumit Kalsi
-
Publication number: 20240352452Abstract: Biotechnological innovations have vastly improved the capacity to perform large-scale protein studies. The production and interrogation of custom protein libraries has proven important for a plethora of biological applications including multiplexed disease diagnostics, therapeutic antibody discovery, and directed evolution. The present invention relates to methods and compositions for use in making Cas-related fusion protein libraries barcoded with sgRNA sequences for applications in protein studies and for protein self-assembly on surfaces.Type: ApplicationFiled: July 11, 2022Publication date: October 24, 2024Inventors: Stephen J. ELLEDGE, Karl W. BARBER
-
Publication number: 20240352453Abstract: Provided herein are compositions and methods of using prime editing systems comprising prime editors and prime editing guide RNAs for treatment of genetic disorders.Type: ApplicationFiled: February 22, 2024Publication date: October 24, 2024Inventors: Wei Hsi YEH, Dewi HARJANTO
-
Publication number: 20240352454Abstract: The embodiments disclosed herein utilized RNA targeting effectors to provide a robust CRISPR-based diagnostic with attomolar sensitivity. Embodiments disclosed herein can detect both DNA and RNA with comparable levels of sensitivity and can differentiate targets from non-targets based on single base pair differences. Moreover, the embodiments disclosed herein can be prepared in freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.Type: ApplicationFiled: February 2, 2024Publication date: October 24, 2024Inventors: Feng Zhang, Jonathan Gootenberg, Omar Abudayyeh
-
Publication number: 20240352455Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.Type: ApplicationFiled: November 3, 2023Publication date: October 24, 2024Inventors: Thazha P. PRAKASH, Punit P. SETH, Eric E. SWAYZE, Mark J. GRAHAM
-
Publication number: 20240352456Abstract: The present invention provides ribonucleotide agents that decrease expression of RIOK3 for the treatment of a sickle cell disease.Type: ApplicationFiled: May 10, 2022Publication date: October 24, 2024Inventors: John Fitzgerald TISDALE, Bjorg GUDMUNDSDOTTIR, Laxminath TUMBURU
-
Publication number: 20240352457Abstract: Provided herein are methods for using RNAi molecules targeting a proteasome beta 5 (PSMB5) gene for controlling Coleopteran insects, methods for producing RNAi molecules targeting PSMB5, and compositions comprising RNAi molecules targeting PSMB5.Type: ApplicationFiled: March 15, 2024Publication date: October 24, 2024Applicant: GreenLight Biosciences, Inc.Inventors: Thais Barros Rodrigues, Suresh D. Desai, Krishnakumar Sridharan
-
Publication number: 20240352458Abstract: The present invention provides novel nucleic acid compound suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.Type: ApplicationFiled: April 2, 2024Publication date: October 24, 2024Inventors: Amy MCCARTHY, Graham CRAGGS, James LONGDEN, Ines DE SANTIAGO, Duncan BROWN, Ahmad Ali MORTAZAVI, Viviana MANNELLA, Muthusamy JAYARAMAN, Alexandre DEBACKER, Adrian James MOGG
-
Publication number: 20240352459Abstract: The present invention is related to the treatment of muscular dystrophy. In particular, compositions of short interfering ribonucleic acids (siRNAs) Eire contemplated that are targeted to different portions of a DUX4 messenger ribonucleic acid molecule. Preferably, these siRNAs are double stranded having a sense strand of fifteen (15) nucleotides. When applied as a therapeutic method, the short interfering ribonucleic acids reduce DUX4 protein translation and mediate a therapeutic response in human facioscapulohumeral muscular dystrophies, FSHD 1 and FSHD2.Type: ApplicationFiled: August 9, 2022Publication date: October 24, 2024Inventors: Charles P. EMERSON, Katelyn DAMAN, Jing YAN, Anastasia KHVOROVA, Annabelle BISCANS, Julia ALTERMAN
-
Publication number: 20240352460Abstract: Provided is snRNA which targets USH2A pre-mRNA. The recognition domain of the snRNA is the reverse complement of a USH2A pre-mRNA sequence. The snRNA binds to the USH2A pre-mRNA to splice and jump exon 13. The snRNA promotes a higher exon 13 skipping efficiency than AON.Type: ApplicationFiled: July 4, 2024Publication date: October 24, 2024Inventors: Junbin Liang, Jiayu Ou, Hui Xu, Simiao Lin
-
Publication number: 20240352461Abstract: The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10 Kb C-to-T, optionally in combination with additional CF therapeutics.Type: ApplicationFiled: July 7, 2024Publication date: October 24, 2024Applicants: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., SpliSense Ltd.Inventors: Bat Sheva KEREM, Efrat OZERI-GALAI, Yifat OREN, Ofra BARCHAD-AVITZUR
-
Publication number: 20240352462Abstract: Disclosed are antisense oligonucleotide inhibitors to MIR-17-92a-1 Cluster Host Gene (MIR 17HG) pre-RNA for treating or ameliorating diseases in which the MIR 17HG pre-RNA plays a role.Type: ApplicationFiled: November 29, 2022Publication date: October 24, 2024Inventors: Nikhil C. Munshi, Eugenio Morelli, Sergei Gryaznov
-
Publication number: 20240352463Abstract: This disclosure relates to a nucleic acid comprising a double stranded RNA molecule comprising sense and antisense strands and further comprising a single stranded DNA molecule covalently linked to the 3? end of either the sense or antisense RNA part of the molecule.Type: ApplicationFiled: December 23, 2021Publication date: October 24, 2024Applicant: ARGONAUTE RNA LIMITEDInventors: Michael Khan, Daniel Mitchell, Johnathan Matlock
-
Publication number: 20240352464Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising additional modification including a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap. The siNA molecules may reduce or inhibit the production of hydroxysteroid dehydrogenase.Type: ApplicationFiled: March 7, 2024Publication date: October 24, 2024Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Xuan Luong, Kellan Passow, Aneerban Bhattacharya, Saul Martinez Montero, Jerome Deval
-
Publication number: 20240352465Abstract: Aspects of the disclosure relate to a gene therapy approach for diseases, disorders, or conditions caused by mutation in the stop codon utilizing modified tRNA. At least 10-15% of all genetic diseases, including muscular dystrophy (e.g. Duchene muscular dystrophy), some cancers, beta thalassemia, Hurler syndrome, and cystic fibrosis, fall into this category. Not to be bound by theory, it is believed that this approach is safer than CRISPR approaches due to minimal off-target effects and the lack of genome level changes.Type: ApplicationFiled: November 13, 2023Publication date: October 24, 2024Inventors: Prashant Mali, Dhruva Katrekar
-
Publication number: 20240352466Abstract: Provided herein are ribonucleic acid compounds comprising an aptamer capable of binding to transferrin receptor (TfR), and a CCAAT/enhancer-binding protein ? (C/EBP?) siRNA. Also provided are pharmaceutical compositions comprising the ribonucleic acid compounds. The compounds and pharmaceutical compositions find use in treating or preventing diseases or disorders, in particular cancers. The compounds also find use in delivering C/EBP? siRNA to a cell.Type: ApplicationFiled: February 21, 2024Publication date: October 24, 2024Inventors: Nagy HABIB, Luis VASCONCELOS
-
Publication number: 20240352467Abstract: A chimeric complex including a nucleic acid aptamer directed against the tyrosine kinase receptor axl in combination with an oligonucleotide containing a DNA sponge directed against miR-214 is provided. Use of the chimeric complex for treatment of tumors is also provided. The treatment inhibits or reduces the onset and/or progression of tumor metastases.Type: ApplicationFiled: August 30, 2022Publication date: October 24, 2024Inventors: Daniela TAVERNA, Lorena QUIRICO, Francesca ORSO
-
Publication number: 20240352468Abstract: The present invention addresses the problem of providing a nucleic acid medicine that is capable of inducing nucleic acid immunity in a cell-specific manner and is capable of capturing and/or inactivating a nucleic acid binding protein for which drug development is difficult. There are provided a hairpin nucleic acid composition that contains two or more kinds of hairpin nucleic acids, and a pharmaceutical composition, a protein function-inhibiting composition, and a cell death-promoting composition that contain the hairpin nucleic acid composition as an active ingredient.Type: ApplicationFiled: June 30, 2022Publication date: October 24, 2024Applicant: THE UNIVERSITY OF TOKYOInventors: Akimitsu OKAMOTO, Kunihiko MORIHIRO
-
Publication number: 20240352469Abstract: The present disclosure provides a method of enzymatically methylating a DNA by combining a source DNA encoding a pro-apoptotic protein, a determinant protein, or a functional fragment thereof, an extracellular methylation enzyme and an enzymatic substrate in an amount sufficient to allow methylation of at least one CpG site on the source DNA and then incubating the reaction sample at a temperature and for a time sufficient to obtain an enzymatically methylated DNA having a specific methylation level or a specific methylation pattern. The disclosure further provides enzymatically methylated DNA, pharmaceutical compositions containing enzymatically methylated DNA, and methods of treatment using such enzymatically methylated DNA or pharmaceutical compositions.Type: ApplicationFiled: August 26, 2022Publication date: October 24, 2024Inventors: Marco PALIZA-CARRE, Shahrokh SHABAHANG, Ge CHEN
-
Publication number: 20240352470Abstract: A composition that comprises recombinant probiotic organisms recombinantly engineered to constitutively express an enzyme involved in maintaining the length of telomeres, wherein the enzyme comprises telomerase subunits, the genetic modification comprises an operon that includes a promoter recognized by the probiotic organism's RNA polymerase and a gene sequence encoding telomerase with genetic modifications that induces secretion of telomerase into a host organism, and the genetic modification of the telomerase gene sequence enhances the telomerase enzyme entrance into the host organism's cells.Type: ApplicationFiled: March 21, 2024Publication date: October 24, 2024Inventor: Jason Ryan Steinbrunn
-
Publication number: 20240352471Abstract: A mycovirus-induced gene silencing vector and a construction method and an application thereof are provided. A nucleotide sequence of the mycovirus-induced gene silencing vector is shown in SEQ ID NO: 2, and construction method for the mycovirus-induced gene silencing vector includes: (1) connecting three single-stranded circular DNA molecules DNA-A, DNA-B and DNA-C of the mycovirus FgGMTV1/HB58 in series and introducing them into a same vector to construct a recombinant vector; and (2) carrying out a deletion mutation on a coding protein p26 of the DNA-C molecule in the recombinant vector to obtain the mycovirus-induced gene silencing vector.Type: ApplicationFiled: December 5, 2023Publication date: October 24, 2024Inventors: Lihua GUO, Chang CHEN, Lihang ZHANG, Shuangchao WANG, Shaojian RUAN, Jun XU, Yijun ZHAO
-
Publication number: 20240352472Abstract: Disclosed herein are novel Pichia pastoris strains for expression of exogenous proteins with substantially homogeneous N-glycans. The strains are genetically engineered to include a mutant OCH1 allele which is transcribed into an mRNA coding for a mutant OCH1 gene product (i.e., ?-1,6-mannosyltransferase, or “OCH1 protein”). The mutant OCH1 protein contains a catalytic domain substantially identical to that of the wild type OCH1 protein, but lacks an N-terminal sequence necessary to target the OCH1 protein to the Golgi apparatus. The strains disclosed herein are robust, stable, and transformable, and the mutant OCH1 allele and the ability to produce substantially homogeneous N-glycans are maintained for generations after rounds of freezing and thawing and after subsequent transformations.Type: ApplicationFiled: November 28, 2023Publication date: October 24, 2024Applicant: Research Corporation Technologies, Inc.Inventors: Kurt R. Gehlsen, Thomas G. Chappell
-
Publication number: 20240352473Abstract: The present disclosure is directed to a novel sequence constructed from viral elements for use as a transgenic promoter; for example, in transgenic plants. More specifically, the present disclosure is directed to a chimeric transgenic promoter sequence comprising a portion derived from the Figwort Mosaic Vims (FMV/FiMV) genome and a portion derived from the Cassava Vein Mosaic Virus (CsVMV) genome. The present disclosure provides methods and compositions for the making and using such a transgenic promoter.Type: ApplicationFiled: August 23, 2022Publication date: October 24, 2024Inventors: Dror Avisar, Shelly Azulay
-
Publication number: 20240352474Abstract: The present disclosure belongs to the technical field of plant genetic engineering. An objective of the present disclosure is to increase an anthocyanidin content of a rice seed. The present disclosure provides use of ZlMYB1 and ZlMYB2 genes from Zizania latifolia in increasing an anthocyanidin content of a rice seed, where the ZlMYB1 gene has the nucleotide sequence set forth in SEQ ID NO: 1; and the ZlMYB2 gene has the nucleotide sequence set forth in SEQ ID NO: 2. In the present disclosure, the ZlMYB1 and ZlMYB2 genes can be effectively overexpressed in rice. When a growth environment is consistent with that of a control plant, rice seeds from a rice plant overexpressing the ZlMYB1 and ZlMYB2 genes turn black and have a significantly increased anthocyanidin content compared with those from the control plant.Type: ApplicationFiled: December 14, 2023Publication date: October 24, 2024Inventors: Ning YAN, Qianqian QI, Yali LI, Xi CHEN, Wanhong LI, Yanning XIE, Yongmei DU, Hongbo ZHANG, Zhongfeng ZHANG
-
Publication number: 20240352475Abstract: The present disclosure provides methods of producing heme proteins in transgenic plants, plant tissues, or plant cells, as well as describing the expression of these heme proteins in seeds. Also, the present disclosure provides transgenic plants expressing the heme proteins, myoglobin and hemoglobin, by introducing and integrating the recombinant DNA constructs into the host genetic material of the subject plants. The specific combination of regulatory elements disclosed herein allows for high heme protein expression level in seeds.Type: ApplicationFiled: April 26, 2024Publication date: October 24, 2024Inventors: Gaston PALADINI, Martin SALINAS, Amit DHINGRA, Henk HOOGENKAMP, Bruce Williamson BENAVIDES, Maria Laura MALVINO, Balaji VASUDEVAN
-
Publication number: 20240352476Abstract: Synthetic promoter artificial DNA for the stable expression of heterologous proteins in plants, the sequence of which is optimized for the overexpression of the target protein in the internal endosperm.Type: ApplicationFiled: August 12, 2022Publication date: October 24, 2024Applicant: TRANSACTIVA S.R.L.Inventor: Piero Cristin
-
Publication number: 20240352477Abstract: The present invention relates to a method for promoting growth of plants. Particularly, the method of the present invention features overexpression of a calcineurin B-like (CBL) interacting protein kinase15 (CIPK15) having an isoleucine (Ile) residue at position 48 (e.g. a CIPK15 from rice) in plants which can promote growth of the plants. The present invention also relates to a recombinant construct comprising a nucleic acid encoding the CIPK15 operably linked to a promoter. The present invention further relates to a transgenic plant overexpressing the CIPK15 exhibiting improved growth compared to a non-transgenic plant counterpart.Type: ApplicationFiled: April 24, 2024Publication date: October 24, 2024Applicant: ACADEMIA SINICAInventors: Su-May YU, Hsiang-Ting LEE, Tuan-Hua David HO
-
Publication number: 20240352478Abstract: The invention relates to a Brassica plant that is resistant to Hyaloperonospora brassicae, which plant may comprise a QTL on chromosome 8, and optionally a QTL on chromosome 4, and/or a QTL on chromosome 1. The presence of the QTL on chromosome 8 can be identified by use of at least one of the markers selected from the group consisting of SEQ ID NOS: 1 to 7; the presence of the QTL on chromosome 4 can be identified by use of at least one of the markers selected from the group consisting of SEQ ID NOS: 8 to 16; and the presence of the QTL on chromosome 1 can be identified by use of at least one of the markers selected from the group consisting of SEQ ID NOS: 17 to 22. The QTL is as comprised in the genome of a Brassica plant representative seed of which was deposited with the NCIMB under accession number NCIMB 43346.Type: ApplicationFiled: April 10, 2024Publication date: October 24, 2024Inventors: Mathieu Pierre Bertrand DETAVERNIER, Martijn DOORNBUSCH, Antje Ulrike Therese KLEWER, Evgeny NOVOSELOV
-
Publication number: 20240352479Abstract: Tomato plants exhibiting resistance to tomato chlorosis virus and Fusarium oxysporum f. sp. lycopersici race 2 are provided, together with methods of producing, identifying, or selecting plants or germplasm with a tomato chlorosis virus and Fusarium oxysporum f. sp. lycopersici race 2 resistance phenotype and lacking an undesirable cold sensitivity trait. Such plants include tomato plants comprising recombinant genomic regions conferring disease resistance. Compositions, including novel polymorphic markers for detecting plants comprising introgressed disease resistance alleles, are further provided.Type: ApplicationFiled: June 7, 2024Publication date: October 24, 2024Inventors: Johannes Hendrikus Maria Barten, Susana Garcia-Andres, Benjamin C. Hunter, Francisco Monci Marin, Maria Belen Salleres Neira
-
Publication number: 20240352480Abstract: A pesticidal protein class exhibiting toxic activity against Coleopteran and Lepidopteran pest species is disclosed, and includes, but is not limited to, TIC7040, TIC7042, TIC7381, TIC7382, TIC7383, TIC7386, TIC7388, and TIC7389. DNA constructs are provided which contain a recombinant nucleic acid sequence encoding the TIC7040, TIC7042, TIC7381, TIC7382, TIC7383, TIC7386, TIC7388, and TIC7389 pesticidal proteins. Transgenic plants, plant cells, seed, and plant parts resistant to Coleopteran and Lepidopteran infestation are provided which contain recombinant nucleic acid sequences encoding the TIC7040, TIC7042, TIC7381, TIC7382, TIC7383, TIC7386, TIC7388, and TIC7389 pesticidal proteins of the present invention.Type: ApplicationFiled: April 5, 2024Publication date: October 24, 2024Inventors: David J. Bowen, Catherine A. Chay, Todd A. Ciche, Stanislaw Flasinski, Arlene R. Howe, Krishnakumar Sridharan
-
Publication number: 20240352481Abstract: Provided herein are IL-2 reporter systems comprising nucleic acid constructs comprising a nucleotide sequence encoding a reporter molecule operably linked to a minimal nuclear factor of activated T cells (NFAT)-responsive promoter. Also provided herein are vectors, cells, and cell lines comprising such nucleic acids. Also provided herein are methods of making and using such cells, for example to measure the ability of a chimeric antigen receptor (CAR) to induce nuclear factor of activated T cells (NFAT)-signaling in a cell.Type: ApplicationFiled: July 29, 2022Publication date: October 24, 2024Applicant: VOR BIOPHARMA INC.Inventors: Brikena Gjeci, Tirtha Chakraborty, Julian Scherer
-
Publication number: 20240352482Abstract: The present disclosure provides a novel genetically modified high productivity VVK-V432C insect cell line derived from the ATCC CRL-1711 cell line. Methods for obtaining this high productivity cell line are also provided.Type: ApplicationFiled: January 16, 2024Publication date: October 24, 2024Inventor: Haifeng Chen
-
Publication number: 20240352483Abstract: The disclosure provides modified rep-cap plasmids containing a tetracycline-inducible expression system that can be used to produce recombinant AAV1 vectors.Type: ApplicationFiled: April 3, 2024Publication date: October 24, 2024Inventors: Sandra Danielle Abbott, Noah Druckenbrod, Tyler Gibson, Kevin Lebo
-
Publication number: 20240352484Abstract: Provided is reward system activation for therapeutic purposes. Accordingly there is provided a method of treating a disease in a subject in need thereof, the method comprising subjecting the subject to a treatment module which activates the reward system of the subject.Type: ApplicationFiled: April 18, 2024Publication date: October 24, 2024Applicants: Technion Research & Development Foundation Limited, Rambam Med-Tech Ltd.Inventors: Asya ROLLS, Lior GEPSTEIN, Hedva HAYKIN, Hilla AZULAY-DEBBY
